ViAqua Therapeutics, a Misgav, Israel-based biotechnology RNA-particle platform promoting and improving animal health in aquaculture, raised $3.4 in funding.
The round was led by S2G Ventures (S2G Oceans & Seafood Fund), Thai Union, and Agriline. Earlier investors Nutreco, Visvires New Protein, The Trendlines Group (SGX:42:T;OTCQX: TRNLY) and the Technion Israel Institute of Technology also participated in this round.
The company intends to use the capital for the commercialization of the first product for health for shrimp and the development of additional products for aquatic animal health and nutrition.
Led by Shai Ufaz, CEO, ViAqua Therapeutics is a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture. Using RNA and an encapsulated delivery method, the company will promote shrimp health in the face of viral challenges, including prevalent and devastating diseases which are widespread in shrimp.
FinSMEs
10/06/2021